$8.11
4.70% day before yesterday
Nasdaq, Sep 06, 10:01 pm CET
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Solid Biosciences Inc. Stock price

$8.11
+0.12 1.50% 1M
-1.31 13.91% 6M
+1.97 32.08% YTD
+4.67 135.76% 1Y
-33.89 80.69% 3Y
-142.19 94.60% 5Y
-331.19 97.61% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.40 4.70%
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Key metrics

Market capitalization $313.01m
Enterprise Value $148.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.62
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-100.03m
Free Cash Flow (TTM) Free Cash Flow $-86.29m
Cash position $190.27m
EPS (TTM) EPS $-3.29
P/E forward negative
Short interest 9.25%
Show more

Is Solid Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Solid Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Solid Biosciences Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Solid Biosciences Inc. forecast:

Buy
100%

Financial data from Solid Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 2.74 2.74
1% 1%
-
-2.74 -2.74
1% 1%
-
- Selling and Administrative Expenses 24 24
1% 1%
-
- Research and Development Expense 70 70
12% 12%
-
-97 -97
8% 8%
-
- Depreciation and Amortization 2.74 2.74
1% 1%
-
EBIT (Operating Income) EBIT -100 -100
8% 8%
-
Net Profit -91 -91
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about Solid Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Solid Biosciences Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired employees.
Neutral
GlobeNewsWire
25 days ago
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
Neutral
GlobeNewsWire
2 months ago
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
More Solid Biosciences Inc. News

Company Profile

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Cumbo
Employees 88
Founded 2013
Website www.solidbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today